Stocktoria
TransMedics Group, Inc. TMDX
TransMedics Group, Inc. (TMDX) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $605.5M at a 31.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.32 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-01 | TD Cowen | Buy (reit) |
| 2026-06-30 | Canaccord Genuity | Buy (main) |
| 2026-06-18 | Stifel | Hold (main) |
| 2026-05-26 | Stifel | Hold (main) |
| 2026-05-06 | Canaccord Genuity | Buy (main) |
| 2026-05-06 | TD Cowen | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.513 |
| Retained earnings / assets | -0.26 |
| EBIT / assets | 0.102 |
| Equity / liabilities | 0.795 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TMDX | TransMedics Group, Inc. | 6/9 | 4.04 | 12.4 | +37.1% |
| AXGN | Axogen, Inc. | 5/9 | -0.43 | — | +20.2% |
| OM | Outset Medical, Inc. | 6/9 | -9.87 | — | +5.1% |
| BLFS | BIOLIFE SOLUTIONS INC | 6/9 | 10.32 | — | +28.9% |
| VASO | VASO Corp | 6/9 | 0.72 | 21.3 | +2.7% |
| CBLL | Ceribell, Inc. | 3/9 | 3.97 | — | +36.1% |
| FOCL | EDAP TMS SA | 3/9 | -5.4 | — | +1.6% |
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
FAQ
Is TMDX financially healthy?
TransMedics Group, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does TMDX pay a dividend?
No, TransMedics Group, Inc. does not currently pay a dividend.
How profitable is TMDX?
In FY2025, TransMedics Group, Inc. had a net margin of 31.4% and a return on equity of 40.2%.
What is TMDX's P/E ratio?
TransMedics Group, Inc.'s trailing price-to-earnings (P/E) ratio is about 12.4×, based on its latest annual earnings.
What is the analyst price target for TMDX?
The average Wall-Street price target for TransMedics Group, Inc. is $117.33, about 34.8% above the recent price, from 9 analysts (consensus: buy).
Is TMDX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on TransMedics Group, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 12.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.